0001415889-24-004123.txt : 20240216
0001415889-24-004123.hdr.sgml : 20240216
20240216162106
ACCESSION NUMBER: 0001415889-24-004123
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240214
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Palleiko Benjamin L
CENTRAL INDEX KEY: 0001366244
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 24648679
MAIL ADDRESS:
STREET 1: C/O KALVISTA PHARMACEUTICALS, INC.
STREET 2: ONE KENDALL SQUARE, BLD 200, STE 2203
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER NAME:
FORMER CONFORMED NAME: Palleiko Ben
DATE OF NAME CHANGE: 20060615
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 200915291
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (857) 999-0075
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
4
1
form4-02162024_090252.xml
X0508
4
2024-02-14
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001366244
Palleiko Benjamin L
C/O KALVISTA PHARMACEUTICALS, INC.
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE
MA
02142
false
true
false
false
CFO, CBO
0
Common Stock
2024-02-14
4
S
0
40855
15.0093
D
159088
D
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
/s/ Benjamin L. Palleiko
2024-02-16